retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity hormone receptor for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Dual and Triple Gut Peptide

Head-to-head comparison studies are needed, but the Triple G weight loss drug may be the best GLP-1 for weight loss and much more

Despite eating so rarely, it maintains blood sugar regulation in a way that intrigued scientists

Newer medications are designed to activate both GLP-1 and GIP receptors at the same time, which may provide a stronger effect on appetite regulation and metabolic health

Data availability statement All data generated or analyzed during this study are included in this published article (and its supplementary information files)

However, as with other peptide systems discussed in this review, such variability often reflects limitations in measurement, context, or study design rather than the absence of biological relevance

10.3390/jcm11133878 71 NauckM